Boucherville, August 20, 2015 – Sandoz Canada Inc., a Novartis company, continues to innovate with the launch of Pr Amiodarone Syringe (PrAmiodarone Hydrochloride for Injection), in a more convenient format for this important medicine which is used in heart rhythm disorders, often used in emergency situations.
